Lantheus (LNTH)
(Delayed Data from NSDQ)
$62.24 USD
+1.78 (2.94%)
Updated Mar 28, 2024 03:59 PM ET
After-Market: $62.23 -0.01 (-0.02%) 7:58 PM ET
1-Strong Buy of 5 1
B Value C Growth F Momentum C VGM
Company Summary
Lantheus Holdings, Inc. is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes. It classifies its products into three categories — Precision Diagnostics (30.1% of FY23 revenues, up 9.4% from FY22), Radiopharmaceutical Oncology (65.9%, up 60.8%), and Strategic Partnerships and Other Revenue (4%, up 10.7%).
Lantheus’ commercial products in our Radiopharmaceutical Oncology category include PYLARIFY (an F 18-labelled prostate-specific membrane antigen (PSMA)-targeted positron emission tomography or PET imaging agent used with PET/computed tomography or CT) and AZEDRA (a radiotherapeutic).
Lantheus&...
Company Summary
Lantheus Holdings, Inc. is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes. It classifies its products into three categories — Precision Diagnostics (30.1% of FY23 revenues, up 9.4% from FY22), Radiopharmaceutical Oncology (65.9%, up 60.8%), and Strategic Partnerships and Other Revenue (4%, up 10.7%).
Lantheus’ commercial products in our Radiopharmaceutical Oncology category include PYLARIFY (an F 18-labelled prostate-specific membrane antigen (PSMA)-targeted positron emission tomography or PET imaging agent used with PET/computed tomography or CT) and AZEDRA (a radiotherapeutic).
Lantheus’ commercial products in its Precision Diagnostics category include DEFINITY (an injectable ultrasound enhancing agent with perflutren-containing lipid microspheres, or microbubbles, that is used in echocardiography examinations), TechneLite (a Technetium or Tc-99m generator that provides the essential nuclear material used by radiopharmacies), NEUROLITE (an injectable, Tc-99m-labeled imaging agent used with single-photon emission computed tomography or SPECT technology), Xenon-133 (a radiopharmaceutical gas) and CARDIOLITE (an injectable, Tc-99m-labeled imaging agent).
Lantheus’ commercial products in its Strategic Partnerships and Other Revenue product category include RELISTOR (a treatment for opioid-induced constipation), Automated Bone Scan Index and aPROMISE (an artificial intelligence medical device software currently sold as PYLARIFY AI in the United States).
Lantheus’ commercial products are used by oncologists, urologists, nuclear medicine physicians, cardiologists, sonographers, technologists, radiologists, and internal medicine physicians working in a variety of clinical settings. The company produces and markets its products across the United States, selling primarily to hospitals, independent diagnostic testing facilities, government facilities and radiopharmacies, among others. Outside the United States, it sells its products via a combination of direct distribution in Canada and third-party distribution relationships in Europe, Canada, Australia, Asia-Pacific, Central America and South America.
General Information
Lantheus Holdings, Inc
201 BURLINGTON ROAD SOUTH BUILDING
BEDFORD, MA 01730
Phone: 978-671-8001
Fax: 978-671-8860
Email: ir@lantheus.com
Industry | Medical - Products |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 12/31/2023 |
Exp Earnings Date | 5/2/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | 1.56 |
Current Year EPS Consensus Estimate | 6.58 |
Estimated Long-Term EPS Growth Rate | NA |
Exp Earnings Date | 5/2/2024 |
Price and Volume Information
Zacks Rank | |
Yesterday's Close | 60.46 |
52 Week High | 100.85 |
52 Week Low | 50.20 |
Beta | 0.55 |
20 Day Moving Average | 889,384.19 |
Target Price Consensus | 92.88 |
4 Week | -7.51 |
12 Week | -3.66 |
YTD | -2.48 |
4 Week | -10.66 |
12 Week | -13.64 |
YTD | -11.38 |
Shares Outstanding (millions) | 68.55 |
Market Capitalization (millions) | 4,144.62 |
Short Ratio | NA |
Last Split Date | NA |
Dividend Yield | 0.00% |
Annual Dividend | $0.00 |
Payout Ratio | 0.00 |
Change in Payout Ratio | 0.00 |
Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
P/E (F1) | 9.19 |
Trailing 12 Months | 9.70 |
PEG Ratio | NA |
vs. Previous Year | 24.22% |
vs. Previous Quarter | 23.26% |
vs. Previous Year | 34.52% |
vs. Previous Quarter | 10.64% |
Price/Book | 5.08 |
Price/Cash Flow | 8.96 |
Price / Sales | 3.20 |
12/31/23 | 63.16 |
9/30/23 | 70.13 |
6/30/23 | 67.18 |
12/31/23 | 27.08 |
9/30/23 | 27.19 |
6/30/23 | 27.42 |
12/31/23 | 5.80 |
9/30/23 | 5.37 |
6/30/23 | 4.88 |
12/31/23 | 5.45 |
9/30/23 | 5.05 |
6/30/23 | 4.55 |
12/31/23 | 30.60 |
9/30/23 | 31.18 |
6/30/23 | 31.10 |
12/31/23 | 25.20 |
9/30/23 | 8.63 |
6/30/23 | 2.97 |
12/31/23 | 31.70 |
9/30/23 | 7.99 |
6/30/23 | 1.72 |
12/31/23 | 11.91 |
9/30/23 | 10.20 |
6/30/23 | 8.08 |
12/31/23 | 10.95 |
9/30/23 | 12.02 |
6/30/23 | 12.92 |
12/31/23 | 0.69 |
9/30/23 | 0.80 |
6/30/23 | 1.01 |
12/31/23 | 40.77 |
9/30/23 | 44.51 |
6/30/23 | 50.30 |